课题基金 / 基金详情

项目摘要

项目成果

MICHAEL TSAI的其他基金

相似基金

相关文献

中文摘要
翻译
北州儿童心血管疾病(CVD)随访研究的目的是确定是否
英文摘要
The purpose of the Upstate KIDS Cardiovascular Disease (CVD) follow-up study is to determine if infertility treatment is associated with a risk of CVD or the timing of puberty. Studies have shown that some pubertal markers appear altered after IVF conception and early adrenarche may itself confer a risk of CVD. Epigenetics may be the mechanism underlying treatment effects. The Upstate KIDS study consisted of children conceived by infertility treatment and children conceived naturally. In this follow-up study, specimens including blood and saliva were taken from children between the ages of 6 and 8. Blood was also taken from mothers to assess confounding by maternal CVD risk.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDIQ BASE BIOMEDICAL ASSAY LABORATORY FOR THE DIVISION OF POPULATION HEALTH RESEARCH - PROJECT TRACKING AND CONSULTATION
  • 批准号:
    10905961
  • 项目类别:
  • 资助金额:
    $2.19万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL TSAI
  • 依托单位:
IDIQ BASE BIOMEDICAL ASSAY LABORATORY FOR THE DIVISION OF POPULATION HEALTH RESEARCH - PROJECT TRACKING AND CONSULTATION
  • 批准号:
    10703545
  • 项目类别:
  • 资助金额:
    $2.16万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL TSAI
  • 依托单位:
COLLABORATIVE PERINATAL PROJECT IN OBESITY GENOME-WIDE ASSOCIATION STUDIES
  • 批准号:
    10670539
  • 项目类别:
  • 资助金额:
    $219.44万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL TSAI
  • 依托单位:
B WELL MOM FATTY ACID PROFILE
  • 批准号:
    10349984
  • 项目类别:
  • 资助金额:
    $1.11万
  • 财政年份:
    2021
  • 负责人:
    MICHAEL TSAI
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: